+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Vetoquinol SA (VETO) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 51 Pages
  • July 2026
  • GlobalData
  • ID: 5997289
Vetoquinol SA (VETO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vetoquinol SA (Vetoquinol), a subsidiary of Soparfin SCA, is a veterinary pharmaceutical company. It develops, produces, and distributes veterinary drugs and non-medicinal products for cats, dogs, cattle, and pigs. The company offers products in therapy areas which include pain, hygiene and care, dermatology, reproduction, mobility and inflammation, udder health, cardio-nephrology and behaviour management. It also offers diagnostics, digital applications, and services. The company distributes its products under brands such as Tolfedine CS, Clindaseptin, Aurizon, Oridermyl, Longamox, and Pen-Histra-Strep, among others. It offers its products to customers, veterinarians, breeders, and pet owners in Europe, the Americas, Africa, the Middle East, Asia and Oceania. Vetoquinol is headquartered in Lure, France.

Vetoquinol SA Key Recent Developments

  • Jun 12, 2026: Partnerships With Vetoquinol
  • Jun 12, 2026: Vetoquinol Sales Third Quarter 2023
  • Apr 28, 2026: Vetoquinol Reports First Quarter 2026 Sales
  • Mar 27, 2026: Vetoquinol Annual Results 2025

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Orano SA - Key Facts
  • Orano SA - Key Employees
  • Orano SA - Key Employee Biographies
  • Orano SA - Major Products and Services
  • Orano SA - History
  • Orano SA - Company Statement
  • Orano SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Orano SA - Business Description
  • Business Segment: Back End
  • Overview
  • Performance
  • Business Segment: Front End
  • Overview
  • Performance
  • Business Segment: Mining
  • Overview
  • Performance
  • Geographical Segment: Africa and Middle East
  • Performance
  • Geographical Segment: Americas
  • Performance
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Europe (Excluding France)
  • Performance
  • Geographical Segment: France
  • Performance
  • R&D Overview
  • Orano SA - Corporate Strategy
  • Orano SA - SWOT Analysis
  • SWOT Analysis - Overview
  • Orano SA - Strengths
  • Orano SA - Weaknesses
  • Orano SA - Opportunities
  • Orano SA - Threats
  • Orano SA - Key Competitors
Section 3 - Company’s Power, Oil & Gas Financial Deals and Alliances
  • Orano SA, Power, Deals By Year, 2020 to YTD 2026
  • Orano SA, Power, Deals By Type, 2020 to YTD 2026
  • Orano SA, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • May 21, 2026: Orano Advances Project IKE with NRC Acceptance for Review of Uranium Enrichment License Application
  • Apr 02, 2026: Orano Signs Agreement With Japanese Client for Spent Fuel Treatment and Continued Bilateral MOX Studies
  • Apr 01, 2026: Orano CE to accept Kayelekera uranium concentrate
  • Mar 17, 2026: Orano and the University of Caen Normandy Sign Partnership Agreement
  • Feb 20, 2026: Orano Reports 2025 Results Above Expectations
  • Jan 06, 2026: Orano Receives 900 Million Dollars From the U.S. Department of Energy to Develop Uranium Enrichment Capacity in the U.S.
  • Dec 04, 2025: Orano Med Enters Next Phase of Collaboration With Roche
  • Jul 03, 2025: Orano's uranium joint venture in Niger on brink of bankruptcy
  • Jun 24, 2025: New permanent appointments for Orano Limited''s Senior Leadership Team
  • Jun 20, 2025: Niger Government plans to nationalise Orano-operated Somair uranium JV
Section 5 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Orano SA, Key Facts
  • Orano SA, Key Employees
  • Orano SA, Key Employee Biographies
  • Orano SA, Major Products and Services
  • Orano SA, History
  • Orano SA, Subsidiaries
  • Orano SA, Joint Venture
  • Orano SA, Key Competitors
  • Orano SA, Power, Deals By Year, 2020 to YTD 2026
  • Orano SA, Power, Deals By Type, 2020 to YTD 2026
  • Orano SA, Recent Deals Summary
List of Figures
  • Orano SA, Power, Deals By Year, 2020 to YTD 2026
  • Orano SA, Power, Deals by Type, 2020 to YTD 2026